CytRx Corporation
CytRx Corporation company was founded in 1985 and is headquartered in Los Angeles, California. CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology.
Contact Details
Office Address
CytRx Corporation
11726 San Vicente Blvd., Suite 650
Los Angeles, CA, USA 90049
Phone: (310) 826-5648
Fax: (310) 826-6139
Executives
Chief Exec. Officer
Mr. Steven A. Kriegsman
VP of Legal Affairs, Corp. Sec. and Gen. Counsel
Mr. Benjamin S. Levin